A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
ImmunoGen, Inc.
Start Date
April 28, 2022
End Date
May 23, 2024
Administered By
Duke Cancer Institute
Awarded By
ImmunoGen, Inc.
Start Date
April 28, 2022
End Date
May 23, 2024